ALEMBIC PHARMA 2018-19 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA 2018-19 Annual Report Analysis
Thu, 13 Jun

ALEMBIC PHARMA has announced its results for the year ended March 2019. Let us have a look at the detailed performance review of the company during FY18-19.

ALEMBIC PHARMA Income Statement Analysis

  • Operating income during the year rose 25.7% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 35.8% YoY during the fiscal. Operating profit margins witnessed a fall and down at 22.2% in FY19 as against 20.5% in FY18.
  • Depreciation charges increased by 9.3% and finance costs increased by 441.5% YoY, respectively.
  • Other income grew by 33.4% YoY.
  • Net profit for the year grew by 41.6% YoY.
  • Net profit margins during the year grew from 13.2% in FY18 to 14.8% in FY19.

ALEMBIC PHARMA Income Statement 2018-19

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Net Sales Rs m 31,308 39,347 25.7%
Other income Rs m 70 94 33.4%
Total Revenues Rs m 31,378 39,441 25.7%
Gross profit Rs m 6,431 8,736 35.8%
Depreciation Rs m 1,055 1,152 9.3%
Interest Rs m 34 184 441.5%
Profit before tax Rs m 5,413 7,493 38.4%
Tax Rs m 1,204 1,568 30.2%
Profit after tax Rs m 4,128 5,844 41.6%
Gross profit margin % 20.5 22.2
Effective tax rate % 22.2 20.9
Net profit margin % 13.2 14.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ALEMBIC PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY19 stood at Rs 15 billion as compared to Rs 11 billion in FY18, thereby witnessing an increase of 32.6%.
  • Long-term debt down at Rs 5 billion as compared to Rs 5 billion during FY18, a fall of 0.1%.
  • Current assets rose 7% and stood at Rs 20 billion, while fixed assets rose 35% and stood at Rs 27 billion in FY19.
  • Overall, the total assets and liabilities for FY19 stood at Rs 48 billion as against Rs 39 billion during FY18, thereby witnessing a growth of 21%.

ALEMBIC PHARMA Balance Sheet as on March 2019

No. of Mths Year Ending 12 Mar-18* 12 Mar-19* % Change
Networth Rs m 22,201 27,188 22.5
 
Current Liabilities Rs m 11,235 14,896 32.6
Long-term Debt Rs m 5,000 4,993 -0.1
Total Liabilities Rs m 39,411 47,778 21.2
 
Current assets Rs m 18,247 19,577 7.3
Fixed Assets Rs m 20,035 27,097 35.2
Total Assets Rs m 39,411 47,778 21.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



ALEMBIC PHARMA Cash Flow Statement Analysis

  • ALEMBIC PHARMA's cash flow from operating activities (CFO) during FY19 stood at Rs 8 billion, an improvement of 159.9% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY19 stood at Rs -8 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY19 stood at Rs 590 million on a YoY basis.
  • Overall, net cash flows for the company during FY19 stood at Rs 1 billion from the Rs -693 million net cash flows seen during FY18.

ALEMBIC PHARMA Cash Flow Statement 2018-19

Particulars No. of months 12 12 % Change
Year Ending Mar-18 Mar-19
Cash Flow from Operating Activities Rs m 3,124 8,120 159.9%
Cash Flow from Investing Activities Rs m -8,844 -7,556 -
Cash Flow from Financing Activities Rs m 5,026 590 -88.3%
Net Cash Flow Rs m -693 1,153 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for ALEMBIC PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 31.0, an improvement from the EPS of Rs 21.9 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 500.2, stands at 15.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.7 times, while the price to sales ratio stands at 2.6 times.
  • The company's price to cash flow (P/CF) ratio stood at 13.3 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Sales per share (Unadj.) Rs 166.1 208.7
TTM Earnings per share Rs 21.9 31.0
Diluted earnings per share Rs 21.9 31.0
Price to Cash Flow x 17.9 13.3
TTM P/E ratio x 15.9 15.9
Price / Book Value ratio x 4.7 3.7
Market Cap Rs m 94,288 94,288
Dividends per share (Unadj.) Rs 4.0 5.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for ALEMBIC PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY19, from 1.6x during FY18. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 41.7x during FY19, from 160.2x during FY18. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 21.5% during FY19, from 18.6% during FY19. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 23.6% during FY19, from 19.7% during FY18. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 12.6% during FY19, from 10.6% during FY18. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-18* 12 Mar-19*
Current ratio x 1.6 1.3
Debtors’ Days Days 61 45
Interest coverage x 160.2 41.7
Debt to equity ratio x 0.2 0.2
Return on assets % 10.6 12.6
Return on equity % 18.6 21.5
Return on capital employed % 19.7 23.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how ALEMBIC PHARMA has performed over the last 5 years, please visit here.

ALEMBIC PHARMA Share Price Performance

Over the last one year, ALEMBIC PHARMA share price has moved up from Rs 490.3 to Rs 500.2, registering a gain of Rs 9.9 or around 2.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,997.8 (down 0.4%). Over the last one year it has moved down from 13,835.1 to 12,997.8, a loss of 837 points (down 6.1%).

Overall, the S&P BSE SENSEX is up 11.2% over the year.

(To know more, check out historical annual results for ALEMBIC PHARMA and quarterly results for ALEMBIC PHARMA)

Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA 2018-19 Annual Report Analysis". Click here!

  

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Buy the Best Safe Stocks in 2020(The 5 Minute Wrapup)

Jan 17, 2020

Don't fall for the safe stocks narrative going around in the stock market these days.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

The Best Asset Class to Invest in 2020(Fast Profits Daily)

Jan 24, 2020

Why I'm most bullish on this asset class above all else in 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ACTAVIS COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS